IRX Stock Overview
InhaleRx Limited engages in the developing and commercializing of medical drug delivery systems in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
InhaleRx Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.028 |
| 52 Week High | AU$0.05 |
| 52 Week Low | AU$0.02 |
| Beta | -0.82 |
| 1 Month Change | -44.00% |
| 3 Month Change | 40.00% |
| 1 Year Change | -37.78% |
| 3 Year Change | -72.00% |
| 5 Year Change | -56.92% |
| Change since IPO | -93.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IRX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -9.7% | 0.5% | 0.9% |
| 1Y | -37.8% | 13.1% | 5.7% |
Return vs Industry: IRX underperformed the Australian Medical Equipment industry which returned 13.1% over the past year.
Return vs Market: IRX underperformed the Australian Market which returned 5.7% over the past year.
Price Volatility
| IRX volatility | |
|---|---|
| IRX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 10.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IRX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO |
|---|---|---|
| 2016 | n/a | Darryl Davies |
| Website |
|---|
| inhalerx.com.au |
InhaleRx Limited engages in the developing and commercializing of medical drug delivery systems in Australia. It also develops inhaled drug formulations. Its solutions include Medihale inhaler, a sealed pod inhaler for use with inhaled formulations.
InhaleRx Limited Fundamentals Summary
| IRX fundamental statistics | |
|---|---|
| Market cap | AU$5.31m |
| Earnings (TTM) | -AU$1.44m |
| Revenue (TTM) | AU$1.20m |
4.4x
P/S Ratio-3.7x
P/E RatioIs IRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRX income statement (TTM) | |
|---|---|
| Revenue | AU$1.20m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.20m |
| Other Expenses | AU$2.65m |
| Earnings | -AU$1.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0076 |
| Gross Margin | 100.00% |
| Net Profit Margin | -119.87% |
| Debt/Equity Ratio | 84.2% |
How did IRX perform over the long term?
See historical performance and comparison